| Price | 5.225 on 13-03-2026 at 16:40:02 |
|---|---|
| Change | 0.00 0% |
| Buy | 0.00 |
| Sell | 0.00 |
| Last Trade: | Unknown 602.00 at 5.225 |
| Day's Volume: | 2,164 |
| Last Close: | 5.225 |
| Open: | 0.00 |
| ISIN: | SE0003815604 |
| Day's Range | 0.00 - 0.00 |
| 52wk Range: | 3.13 - 6.55 |
| Market Capitalisation: | - |
| VWAP: | 5.235827 |
| Shares in Issue: | 395.16m |
Egetis Therapeu (0ABW) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 602 | 5.225 | SI Trade |
12:39:19 - 13-Mar-26 |
| Unknown* | 190 | 5.24 | SI Trade |
11:46:06 - 13-Mar-26 |
| Unknown* | 190 | 5.24 | SI Trade |
11:46:06 - 13-Mar-26 |
| Unknown* | 591 | 5.24 | SI Trade |
11:10:04 - 13-Mar-26 |
| Unknown* | 591 | 5.24 | SI Trade |
11:10:04 - 13-Mar-26 |
| Unknown* | 1,819 | 5.32 | SI Trade |
14:30:14 - 12-Mar-26 |
| Unknown* | 2,863 | 5.29 | SI Trade |
11:38:40 - 12-Mar-26 |
| Unknown* | 1,000 | 5.225 | SI Trade |
13:39:08 - 11-Mar-26 |
| Unknown* | 1,000 | 5.225 | SI Trade |
13:39:08 - 11-Mar-26 |
| Unknown* | 5,000 | 5.35 | SI Trade |
14:14:28 - 10-Mar-26 |
Egetis Therapeu (0ABW) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 12th Mar 2026 11:02 am | RNS | NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) |
| 12th Mar 2026 11:02 am | MFN | NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) |
| 26th Feb 2026 6:00 am | MFN | Year-End Report January-December 2025 |
| 29th Jan 2026 6:00 am | MFN | Egetis Completes the U.S. Rolling NDA Submission for Emcitate® (tiratricol) for Treatment of MCT8 Deficiency |
| 30th Dec 2025 7:00 am | MFN | Change in the number of ordinary shares and votes in Egetis Therapeutics |
| 19th Dec 2025 6:00 am | RNS | Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency |
| 19th Dec 2025 6:00 am | MFN | Egetis Therapeutics initiates New Drug Application in the USA for Emcitate® (tiratricol) for MCT8 deficiency |
| 25th Nov 2025 6:00 am | MFN | Interim report Q3 2025 |
| 14th Nov 2025 6:00 am | MFN | Egetis announces positive results from the ReTRIACt study of Emcitate® (tiratricol) in MCT8 deficiency |
